HIỆU QUẢ ĐIỀU TRỊ CỦA ENZALUTAMIDE TRÊN BỆNH NHÂN UNG THƯ TUYẾN TIỀN LIỆT GIAI ĐOẠN DI CĂN

Abstract

Objective: To describe some clinical and subclinical features and the efficacy of enzalutamide in patients with metastatic stage of prostate cancer. Patients and methods: Describing a clinical case series of 20 patients with metastatic stage of prostate cancer treated with enzalutamide in Vietnam National Cancer Hospital from 01/2020 through 5/2023. Results: - 10 mCRPC patients who failed treatment with ADT combined with abiraterone acetate and/or docetaxel, with mean age of 70,2 (58-77). The mean pre-treatment PSA level was 380.4 ng/ml (7,5-750,8), mean PSA nadir was 300,4 ng/ml (3,4-750,8), PSA response was achieved in 2/10 patients, 6/10 patients had clinical response, mean PFS-PSA was 3,5 months (3-7 months), and mean TTF was 4,8 months (3-10 months). - 10 mHSPC patients, with mean age of 75,5 (68-85), 7/10 patients had high metastatic burden. The mean pre-treatment PSA level was 80,5 ng/ml (40,3-180,5), mean PSA nadir was 1.2 ng/ml (0.02-10.4), PSA response was achieved in all 10 patients, and 6/6 had complete clinical response. No patients experienced adverse effects. Conclusion: The mean PFS-PSA in mCRPC patients was 3,5 months (3-7 months), and mean TTF was 4,8 months (3-10 months). The mean PSA nadir in the mHSPC group was 1,2 ng/ml (0.02-10.4 ng/ml), and all 10 patients achieved PSA response.